FDA_Warning_Letters, Import_Alerts_&_EU_Non-Compliances_in_2019
X

Find Approved Drugs for Infections and Infectious Diseases in Clinical Development

A collaboration with SCORR Marketing

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Country filter
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            refresh

            Product Type

            Companies

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Daptomycin

            Therapeutic Area: Infections and Infectious Diseases

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Sandoz

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Acquisition March 23, 2020

            Details:

            Sandoz acquires the distribution rights in the United States for daptomycin 500mg injection and fosaprepitant 150mg for injection from BE Pharmaceuticals AG.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Crofelemer

            Therapeutic Area: Infections and Infectious Diseases

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Iliad Research and Trading

            Deal Size: $0.4 million Upfront Cash: Undisclosed

            Deal Type: Agreement March 05, 2020

            Details:

            Transaction Proceeds Will be Allocated to Support Advancement of Regulatory Activities Associated with Jaguar's Pipeline, Including the Company's Lead Product Candidate, Crofelemer.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Omeprazole Magnesium,Amoxycillin,Rifabutin

            Therapeutic Area: Infections and Infectious Diseases

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: HealthCare Royalty Partners

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Financing February 25, 2020

            Details:

            The non-dilutive financing will support the acquisition of rights to Movantik® from AstraZeneca, the planned U.S. launch of Talicia® this quarter and the ongoing promotion of Aemcolo®.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Acyclovir,Hydrocortisone

            Therapeutic Area: Infections and Infectious Diseases

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Shijiazhuang Yuanmai Biotechnology

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement February 24, 2020

            Details:

            The agreement gives SYB the right to register, manufacture and market the product in China.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Diclazuril,Methyl 4-Hydroxybenzoate,Propyl 4-Hydroxybenzoate

            Therapeutic Area: Infections and Infectious Diseases

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Merck Animal Health

            Deal Size: $55.0 million Upfront Cash: $55.0 million

            Deal Type: Agreement February 19, 2020

            Details:

            Vecoxan joins Elanco’s previously announced Osurnia® and Capstar® divestitures, and divestiture of European Economic Area and U.K.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Miconazole

            Therapeutic Area: Infections and Infectious Diseases

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: m8 Pharmaceuticals

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement February 18, 2020

            Details:

            m8 Pharmaceuticals and Vectans Pharma have signed an exclusive licensing agreement whereby m8 will have the rights to register and commercialize Loramyc® (miconazole) for Mexico and Brazil.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Eravacycline

            Therapeutic Area: Infections and Infectious Diseases

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Armistice Capital

            Deal Size: $17.5 million Upfront Cash: Undisclosed

            Deal Type: Financing January 22, 2020

            Details:

            The company intends to use the net proceeds from the registered direct offering and concurrent private placement for the commercialization of XERAVA as well as for working capital and other general corporate purposes.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Omeprazole Magnesium,Amoxycillin,Rifabutin

            Therapeutic Area: Infections and Infectious Diseases

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Entera Health

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Termination Agreement January 21, 2020

            Details:

            RedHill provided a notice of termination to Entera Health regarding the license agreement for EnteraGam® and the co-promotion agreement with Advanz Pharma Corp. for Donnatal® will not be renewed.